Folisurge 150IU injection contains Follitropin alfa as its active component, a synthetic form of follicle-stimulating hormone (FSH). This medication is a key component in assisted reproductive technologies (ART), addressing infertility in both men and women, defined as the inability to conceive after a year of regular unprotected intercourse. In women, Folisurge 150IU stimulates the development of multiple ovarian follicles, which are crucial for egg maturation. In men, it plays a vital role in enhancing sperm production. By providing precise timing for optimal ovulation in women, it significantly increases pregnancy rates and can shorten the overall treatment duration, offering hope to infertile couples due to its proven efficacy and generally safe profile.
However, certain conditions necessitate avoiding the use of Folisurge 150IU injection. Individuals with a known hypersensitivity or allergic reaction to Folisurge 150IU injection or any of its components must not use it. While rare, allergic reactions are possible and require immediate medical attention if they occur. Women diagnosed with ovarian cysts or tumors should avoid this injection, as it has the potential to exacerbate these existing conditions. Patients with uncontrolled hypothyroidism or adrenal dysfunction are also advised against using Folisurge 150IU injection; uncontrolled hypothyroidism specifically refers to a state where thyroid hormone levels remain inadequately regulated, leading to persistent symptoms and potential complications. Furthermore, individuals with anatomical abnormalities or blockages within their reproductive tract that prevent the successful transport of eggs or sperm may not derive therapeutic benefit from this medication. Lastly, Folisurge 150IU injection is generally not recommended for use in pediatric or elderly populations due to unestablished safety and efficacy in these age groups.
